creatine (PD-02) / Avicenna Pharma - LARVOL DELTA

[VIRTUAL] Inhibiting TGF-β and IL-6 Receptors Enhance Pancreatic Cancer Apoptosis (SSO 2021) - " We determined IL-6 expression (ELISA assay) in a patient-derived PDAC cell line (PD002) and multiple commercially available PDAC cell lines (PANC-1, AsPC1, Capan-1, Capan-2) at baseline and following treatment with TGF-β or galunisertib (TGF-β receptor inhibitor)...Tocilizumab and galunisertib, in combination with gemcitabine, yielded the lowest expression of activated p-p38MAPK... We demonstrated that blockade of TGF-β signaling alone results in a reduction of IL-6 expression. We potentially identified a poorly understood off-target effect of galunisertib activating p38MAPK which may have untoward clinical effects. TGF-β receptor inhibition in combination with IL-6 receptor inhibition and chemotherapy was significantly anti-proliferative and pro-apoptotic overall suggesting a mechanism to overcome the untoward effects of TGF-β receptor inhibition."

Cachexia • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BCL2L1 • IL6 • TGFB1

[VIRTUAL] PDW02. Reducing the Bias: Ways Perceptions Influence Behavior and How We Can Do Better (ENDO 2021) - "This session will explore conscious and unconscious bias towards individuals of different groups, its impact on research and healthcare outcomes, and techniques for reducing and/or working to eliminate bia, including allyship. A Q&A session will follow the presentation."

DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors. (PubMed, J Med Chem) - "DPAGT1 inhibition by CPPB leads to a reduced expression level of Snail, but does not reduce E-cadherin expression level at the IC50 (DPAGT1) concentration. CPPB displays a strong synergistic effect with paclitaxel against growth-inhibitory action of a patient-derived pancreatic adenocarcinoma, PD002: paclitaxel (IC50 1.25 uM) inhibits growth of PD002 at 0.0024-0.16 uM in combination with 0.10-2.0 uM of CPPB (IC50 35 uM)."

Journal • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CDH1

[VIRTUAL] PD02: Kidney Cancer: Localized: Surgical Therapy I (AUA 2020) - No abstract available

PD02. ENDO Career Fair (ENDO 2020) - "Plan to attend the ENDO Career Fair. No matter your career stage, this is an invaluable opportunity to network with job recruiters and potential employers and learn about available opportunities."

Genetic bioaugmentation of activated sludge with dioxin-catabolic plasmids harbored by Rhodococcus sp. strain p52. (PubMed, Environ Sci Technol) - "Moreover, transconjugants harboring pDF01 and pDF02 were isolated from the bioaugmented SBR after 2 days, and their abilities to degrade dibenzofuran were confirmed...Evaluation of the bacterial community profile of sludge by high-throughput 16S rRNA gene sequencing revealed that genetic bioaugmentation led to a bacterial community with an even distribution of genera in the SBR. This study demonstrates the promise of genetic bioaugmentation with catabolic plasmids for dioxins remediation."

Journal

PDW02-Reproducibility for Everyone (Neuroscience 2019) - "This workshop will introduce you to reproducible workflows and a range of tools along the themes of organization, documentation, analysis, and dissemination. It will consist of a 90-minute interactive session followed by a 30-minute Q&A session with the instructors"